WuXi XDC Cayman Inc. ("WuXi XDC" or "the Group", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, is pleased to announce its annual results and corporate updates for the year ended 31 December 2023.
WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platform technologies, announced today that they have reached a comprehensive partnership in drug-linker technology, which is co-developed with HySlink Therapeutics ("HySlink"), and CRDMO services spanning from discovery to commercialization. WuXi XD
WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company specialized in researching, developing and manufacturing innovative therapeutics that improve people's lives worldwide, announced that they have signed a Memorandum of Understanding (MOU) for comprehensive and integrated services which refer to the developmen